🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Today, our partner Former Account of Eli Lilly and Company presented encouraging new data from a Phase 1b study of our novel T regulatory cell stimulator, NKTR-358, in patients with #atopicdermatitis. Read about these findings’ potential for treating #autoimmune disorders: bit.ly/3ITS8uI

We’re excited about the potential of our NKTR-358 program in partnership with Former Account of Eli Lilly and Company to treat #autoimmune disorders and restore the immune system balance with T regulatory cells. Learn more about this first-in-class IL-2 agonist: bit.ly/3p0LZFs

At #JPM2022 next week, Company management will present on the exciting advances we are making across our #immunooncology and #immunotherapy pipelines. Learn more about our programs: bit.ly/3vDhAfY

It’s #NationalMentoringMonth, and we’re celebrating the valuable impact mentors have in #biotech and #STEM. Our team is proud to support the next generation, which you can read about here: bit.ly/3KeYkOq

We’re pleased to share a new manuscript in Future Science Group on the currently enrolling PIVOT-12 Phase 3 study evaluating BEMPEG (NKTR-214) for adjuvant use in patients with resected #melanoma. Read here: bit.ly/3o9bp2o

Today is #WorldCancerDay. Our team is privileged to work at the cutting edge of science and #oncology to create potential new #cancer therapies for people impacted by these debilitating diseases. Learn about our commitment: bit.ly/32zJ4L3

This International Day of Women and Girls in Science #IDWGS, we’re celebrating NexGeneGirls, an organization providing opportunities and mentorship in our local communities. Together, we are empowering the next generation of #girlsinSTEM. Learn more: bit.ly/3uGQ5FM

Proud partners of the organization, we’re featuring Women In Bio during #IDWGS 2022. Offering career support, mentorship and training for women in #biotech, they’ve created a diverse and inclusive community of #womeninSTEM. Read more: bit.ly/3slQrih

In honor of #EmployeeAppreciationDay, we’re celebrating and expressing gratitude for our team! Thanks for your dedication to patients as we advance potential #immunotherapies and for making Nektar a rewarding place to work. Learn more about us: bit.ly/3BVuzxw

This #InternationalWomensDay, we’re saying thank you to all the women on our team developing innovative #immunotherapy treatments! Nektar is also proud to work with organizations supporting the advancement of #WomeninSTEM. #IWD2022

It’s #AutoimmuneDiseaseAwarenessMonth. Dedicated to developing novel therapies for patients affected by #autoimmunediseases, we are evaluating NKTR-358, our investigational therapeutic candidate, in multiple trials. Learn more: bit.ly/3p0LZFs

We’re looking forward to the #EADVCongress kicking off today, where we’re presenting Phase 1b data for REZPEG (NKTR-358) in Atopic Dermatitis and Psoriasis. Click here for our full data press release: bit.ly/3QnapTH

Christie Fanton, Ph.D., our VP of Translational Medicine published an article discussing her thoughts on the current treatment landscape in AD & why REZPEG could be the key to restoring balance in the immune system to treat the disease. Full article here: bit.ly/3TZOFAq

Thank you EADV & our presenters for a great #EADVCongress! We’re excited about the potential of NKTR-358 to address the imbalance in the immune system that causes autoimmune disorders & chronic inflammatory conditions. Explore our posters: bit.ly/3RST8mo

This #BloodCancerAwarenessMonth, we’re evaluating a novel IL-15 agonist NKTR-255 as a potential treatment for patients with #multiplemyeloma, #nonHodgkinlymphoma and #DLBCL. Together we can #CancelBloodCancer. Learn more: bit.ly/3vDhAfY

On #WorldCancerResearchDay, we thank our patients & team of dedicated scientists and clinicians for continuing in the fight against cancer. Learn how IL-15 agonist NKTR-255 is designed to boost the immune system’s natural ability to fight cancer: bit.ly/38P5BD5

We’re gearing up for #SITC22 this year, where Nektar is presenting data including the first preclinical findings from our research program, NKTR-288, a novel interferon gamma mutein. Click here to learn more: bit.ly/3SJa2VA

At #ASH2022, Nektar is presenting data and a new clinical study design for NKTR-255, our novel, polymer-conjugated IL-15 agonist, being studied in a variety of #cancer types. Learn more: bit.ly/38P5BD5